BTCC / BTCC Square / Global Cryptocurrency /
AICoin AI: Eli Lilly’s $2.75B Bet on AI Drug Development Mirrors Crypto Funding Models

AICoin AI: Eli Lilly’s $2.75B Bet on AI Drug Development Mirrors Crypto Funding Models

Published:
2026-03-30 13:40:11
19
3
AICoin AI News -

Pharmaceutical giant Eli Lilly has committed up to $2.75 billion to license AI-developed drug candidates from Insilico Medicine, signaling growing institutional adoption of generative AI in biotech. The deal includes a $115 million upfront payment with the remaining value tied to milestones—a structure reminiscent of crypto project funding rounds where initial capital unlocks development phases.

Insilico's pipeline includes 28+ AI-generated therapeutics, with nearly half already in clinical trials. This mirrors the rapid iteration seen in blockchain projects like Ethereum's Layer 2 solutions or Solana's high-throughput ecosystem, where technical milestones trigger further investment.

The partnership may indirectly benefit AI-focused crypto projects (FET, AGIX, OCEAN) as institutional validation of generative AI accelerates. Pharmaceutical companies increasingly resemble crypto VCs—placing multiple bets on emerging tech, with payouts weighted toward successful outcomes.

|Square

Get the BTCC app to start your crypto journey

Get started today Scan to join our 100M+ users

All articles reposted on this platform are sourced from public networks and are intended solely for the purpose of disseminating industry information. They do not represent any official stance of BTCC. All intellectual property rights belong to their original authors. If you believe any content infringes upon your rights or is suspected of copyright violation, please contact us at [email protected]. We will address the matter promptly and in accordance with applicable laws.BTCC makes no explicit or implied warranties regarding the accuracy, timeliness, or completeness of the republished information and assumes no direct or indirect liability for any consequences arising from reliance on such content. All materials are provided for industry research reference only and shall not be construed as investment, legal, or business advice. BTCC bears no legal responsibility for any actions taken based on the content provided herein.